Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis
Clinical Gastroenterology and Hepatology · 2026-03 · 24 (3) · 784-793
DOI: 10.1016/j.cgh.2025.07.025 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-03. Verfasst von Sailish Honap und 30 weiteren Autor:innen. Beteiligte Einrichtung: School of Immunology and Microbial Sciences, King's College London, United Kingdom; Department of Gastroenterology, St George's University Hospitals …. Hauptthemen laut MEDLINE: Pyrimidines, Heterocyclic Compounds, 3-Ring, Colitis, Ulcerative, Piperidines. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND & AIMS: Tofacitinib and upadacitinib are Janus kinase (JAK) inhibitors that are increasingly used for the treatment of acute severe ulcerative colitis (ASUC). However, comparative analyses of safety and effectiveness have not been performed for their use in this setting. METHODS: This multicenter, retrospective study enrolled hospitalized adult patients treated with tofacitinib or upadacitinib for ASUC between January 2019 and June 2024. The main outcomes were clinical response, clinical remission, and colectomy-free survival. Propensity-adjusted analyses using inverse probability treatment weighting, and double robust estimations were used to control for confounding factors. RESULTS: In total, 111 patients (60 tofacitinib, 51 upadacitinib) were enrolled across 23 international centers. JAK inhibitors were used to induce response in 86 patients (77%) and used to maintain response after adequate intravenous steroid response in 25 (23%). The median follow up was 31 weeks (interquartile range, 13-64 weeks). Between days 3 and 7 after treatment initiation, upadacitinib was associated with greater response rates (84% vs 54%; P = .02), but response/remission was comparable at day 98 (45%/36% vs 55%/48%) and day 182 (29/29% vs 39/34%). Sub-analyses for JAK inhibitor use as salvage therapy (tofacitinib [n = 35] vs upadacitinib [n = 31]) showed similar effectiveness outcomes across both groups. The probabilities of colectomy-free survival at days 98 and 182 for tofacitinib and upadacitinib were 79% and 75% and 80% and 78%, respectively, with no significant differences in the comparison of survival curves (P = .99). Treatment failure rates (where JAK inhibitors were used to maintain remission) were similar at days 98 and 182. The frequency of adverse events was comparable. CONCLUSIONS: Tofacitinib and upadacitinib appear to have similar effectiveness and safety profiles when used for the treatment of ASUC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Immunology and Microbial Sciences, King's College London, United Kingdom; Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: sail…
- Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
- Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, United Kingdom; Institute of Infection and Immunity, City St George's, University of London, London, United Kingdom.
- Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, United Kingdom.
- CHU Nantes, Institut des Maladies de l'Appareil Digestif, CIC Inserm 1413, Université de Nantes, Nantes, France.
- Université de Lorraine, CHRU, Inserm, NGERE, Nancy, France.
Zitieren
APA
Honap, S., St-Pierre, J., Colwill, M., Patel, K., Le Berre, C., Caron, B., Nogami, A., Kobayashi, T., Altwegg, R., Laharie, D., Hebuterne, X., Nachury, M., Roblin, X., Uzzan, M., Kotze, P. G., Lukáš, M., Vieujean, S., D'Amico, F., Albshesh, A., …, & ATTRACT Study Group (2026). Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 24(3), 784-793. https://doi.org/10.1016/j.cgh.2025.07.025
Vancouver
Honap S, St-Pierre J, Colwill M, Patel K, Le Berre C, Caron B, et al. Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis. Clinical Gastroenterology and Hepatology. 2026;24(3):784-793. doi:10.1016/j.cgh.2025.07.025
BibTeX
@article{Honap2026,
author = {Honap, Sailish and St-Pierre, Joelle and Colwill, Michael and Patel, Kamal and Le Berre, Catherine and Caron, Bénédicte and Nogami, Akira and Kobayashi, Taku and Altwegg, Romain and Laharie, David and Hebuterne, Xavier and Nachury, Maria and Roblin, Xavier and Uzzan, Mathieu and Kotze, Paulo Gustavo and Lukáš, Milan and Vieujean, Sophie and D'Amico, Ferdinando and Albshesh, Ahmad and Guillo, Lucas and Fumery, Mathurin and Nancey, Stephane and Ye, Byong Duk and Bergemalm, Daniel and Halfvarson, Jonas and Buisson, Anthony and Karmiris, Konstantinos and Rubin, David T and Vicaut, Eric and Peyrin-Biroulet, Laurent and ATTRACT Study Group, ATTRACT Study Group},
title = {Comparative Effectiveness of Tofacitinib vs Upadacitinib for the Treatment of Acute Severe Ulcerative Colitis},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {3},
pages = {784--793},
doi = {10.1016/j.cgh.2025.07.025}
}
EUVIMED